Explore how the ratio of pd-1+ treg to ctl and the presence of tertiary lymphoid structures can influence treatment outcomes ...

Cancer-fighting T-cells, the immune system's primary enforcers, are scarce in the rare kidney cancer called chromophobe renal ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type-1 diabetes, hepatitis, ...

New research from UC Davis Comprehensive Cancer Center has uncovered an evolutionary change that may explain why certain ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

Scientists at UC Davis discovered a small genetic difference that could explain why humans are more prone to certain cancers ...

In healthy adults, a single low dose of IMP761 continues to be safe and appears to reduce the activity of T-cells, a clinical ...

Engineered chip mimics bone marrow and immune system, offering a faster, tailored path for cancer immunotherapy.

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Melbourne scientists have shown for the first time how a “revolutionary” blood cancer treatment could be tweaked to also cure ...

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...